CLARIX analyzes all 23 pairs of chromosomes

Other available tests on the market have proven to be unsafe and less effective, given the fact that they fail to analyze each chromosome while also being invasive.
Chromosomes are structures that carry our DNA. In humans, each cell contains 23 pairs of chromosomes, for a total of 46. Of these chromosomes, 23 come from the mother and 23 from the father.

The presence or absence of extra or missing chromosomes can cause serious health issues for future baby or babies, which can lead to the development of syndromes such as Down syndrome, and Turner syndrome, among others.

Our CLARIX plus test

has the advantage of being able to analyze each of the pairs of chromosomes to detect gain or loss, while other similar invasive tests only analyze part of the genetic information and not the entire chromosome set.

As we age, the risk of conceiving a baby with a chromosomal anomaly increases.

Women who become pregnant over the age of 40 carry the greatest chance of having a baby with a chromosomal abnormality.

This graph shows the estimated risk of having a baby with Down Syndrome in relation to the mother’s age.

What is the purpose of Clarix?

Clarix helps identify numerical chromosomal abnormalities in the early stages of development, regardless of whether the baby was conceived spontaneously or with the help of assisted reproductive technology treatments.

This method offers a 99% effectiveness rate.
Our non-invasive prenatal test allows our specialists to analyze the genetic material of the future baby by examining the cell-free DNA present in the mother's blood during pregnancy. This test is conducted without interfering with the baby’s development, enabling us to detect any chromosomal numerical abnormalities, such as Down Syndrome, at an early stage. At the same time, it also determines the baby's gender.

Is there any risk involved in performing a prenatal test?

Nowadays, there are several types of prenatal tests, which are classified according to the method of obtaining the sample and the type of analysis that is carried out.
Depending on the method used to obtain the sample, we can find invasive methods such as amniocentesis, cordocentesis, and chorionic villus sampling, which may pose a risk to achieving a full-term pregnancy (with a 5% risk of miscarriage).

However, at Ingenes, we opt for noninvasive methods, such as Clarix, which pose no risk for the mother or the future child or children, as the sample is sourced from fetal cell-free DNA found in the mother’s bloodstream.

Who is Clarix intended for?

•This screening test is ideal for expectant mothers who have become pregnant spontaneously or through Assisted Reproductive Technology Treatments.

• Expectant mothers with advanced maternal age may be prone to developing chromosomal abnormalities (women over 35 years of age).

• Expectant mothers who wish to discover their baby’s gender as early as the 10th gestational week.

•Patients who have undergone an Assisted Reproduction Treatment without the screening of a Preimplantation Genetic Testing for aneuploidies (PGT-A).

•At Ingenes, the Clarix test can be used with singleton and twin pregnancies.

What are the benefits of using Clarix?

This test can serve as a complement to ultrasound and standard fetal risk screening carried out during the first trimester.

The main benefit is the early detection of the most critical chromosomal abnormalities, this allows us to provide you with any necessary guidance, and obtaining this information at the right time is key in the decision-making process to guarantee you and your baby’s well-being.

Gender determination: A baby’s gender may be determined by ultrasound, a specialized physician should be able to confirm or predict this by week 16 of gestation. With our test, we can accurately determine a baby’s gender by the 10th gestational week.

This is a non-invasive, low-risk test, and providing a sample for examination is simple and easy. The results of your test will be available within 10 days.

How does Clarix work?

Clarix is carried out the following way:
The test must be carried out at the Maternal-Fetal Medicine Unit by an Assisted Reproduction specialist.
A blood sample is collected from the mother, without interfering with the baby's development. Fetal DNA is then obtained from this sample by using advanced molecular biology techniques using the best technology available in the market, Next Generation Sequencing (NGS).
Genomic analysis is carried out, where the results demonstrate the probability of conceiving a baby with aneuploidy (gain or loss in the number of chromosomes), and at the same time, it allows us to identify the sex of the baby in the early weeks of pregnancy.

What should you do if you receive an abnormal result?

If your results are abnormal or you have any questions, we offer you the option of reviewing your results at the Maternal-Fetal unit schedule an appointment with our clinical geneticists to learn more about your options.
In case you already have a Maternal-Fetal Control physician, you can still have this test done at Ingenes and provide your results to your specialist.

Find the best option for you with Clarix

If you have questions about Clarix or are considering choosing this test to ease your mind and gain full confidence about you and your baby's health, reach out to your Maternal-Fetal expert, and they'll guide you through this process.

Ask the Maternal-Fetal specialist leading your case if this is the right option for you, and he or she will point you in the right direction.

Leave your baby's health in expert hands!

Our research team is dedicated to innovation and education in reproductive sciences, developing cutting-edge technology and tests such as CLARIX in partnership with renowned researchers from Cinvestav-IPN.

Get the peace of mind you need with the help of Clarix noninvasive prenatal test

Book an appointment to carry out this noninvasive prenatal test, starting from the 10th gestational week, click below to book your appointment.

Begin here
Permiso Cofepris: 133300201A1156
Dr. Felipe Camargo Cédula Profesional SEP: 4452501
©Todos los derechos reservados 2024. Instituto Ingenes, Fertilidad & Genética